Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease in Phase 1, Phase 1b/2a and Phase 1b Studies

January 6, 2023

https://www.globenewswire.com/news-release/2023/01/06/2584421/0/en/Celularity-s-Placental-Derived-Allogeneic-Cell-Therapy-Provides-Clinically-Meaningful-Benefit-and-Durable-Biological-Effect-in-Patients-with-Moderate-to-Severe-Crohn-s-Disease-in-P.html

Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies

Data support further investigation of novel genetically modified cell therapy in Crohn’s disease

Read more at globenewswire.com

Related news for (CELU)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.